Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 130

1.

Disrupted salience network dynamics in Parkinson's disease patients with impulse control disorders.

Navalpotro-Gomez I, Kim J, Paz-Alonso PM, Delgado-Alvarado M, Quiroga-Varela A, Jimenez-Urbieta H, Carreiras M, Strafella AP, Rodriguez-Oroz MC.

Parkinsonism Relat Disord. 2020 Jan;70:74-81. doi: 10.1016/j.parkreldis.2019.12.009. Epub 2019 Dec 16.

PMID:
31881521
2.

Abnormal pattern of brain glucose metabolism in Parkinson's disease: replication in three European cohorts.

Meles SK, Renken RJ, Pagani M, Teune LK, Arnaldi D, Morbelli S, Nobili F, van Laar T, Obeso JA, Rodríguez-Oroz MC, Leenders KL.

Eur J Nucl Med Mol Imaging. 2020 Feb;47(2):437-450. doi: 10.1007/s00259-019-04570-7. Epub 2019 Nov 25.

3.

Functional inhibitory control dynamics in impulse control disorders in Parkinson's disease.

Paz-Alonso PM, Navalpotro-Gomez I, Boddy P, Dacosta-Aguayo R, Delgado-Alvarado M, Quiroga-Varela A, Jimenez-Urbieta H, Carreiras M, Rodriguez-Oroz MC.

Mov Disord. 2020 Feb;35(2):316-325. doi: 10.1002/mds.27885. Epub 2019 Nov 11.

PMID:
31710401
4.

Nigrostriatal dopamine transporter availability, and its metabolic and clinical correlates in Parkinson's disease patients with impulse control disorders.

Navalpotro-Gomez I, Dacosta-Aguayo R, Molinet-Dronda F, Martin-Bastida A, Botas-Peñin A, Jimenez-Urbieta H, Delgado-Alvarado M, Gago B, Quiroga-Varela A, Rodriguez-Oroz MC.

Eur J Nucl Med Mol Imaging. 2019 Sep;46(10):2065-2076. doi: 10.1007/s00259-019-04396-3. Epub 2019 Jul 4.

PMID:
31273436
5.

Neuroimaging biomarkers for clinical trials in atypical parkinsonian disorders: Proposal for a Neuroimaging Biomarker Utility System.

van Eimeren T, Antonini A, Berg D, Bohnen N, Ceravolo R, Drzezga A, Höglinger GU, Higuchi M, Lehericy S, Lewis S, Monchi O, Nestor P, Ondrus M, Pavese N, Peralta MC, Piccini P, Pineda-Pardo JÁ, Rektorová I, Rodríguez-Oroz M, Rominger A, Seppi K, Stoessl AJ, Tessitore A, Thobois S, Kaasinen V, Wenning G, Siebner HR, Strafella AP, Rowe JB.

Alzheimers Dement (Amst). 2019 Apr 2;11:301-309. doi: 10.1016/j.dadm.2019.01.011. eCollection 2019 Dec.

6.

Pramipexole-induced impulsivity in mildparkinsonian rats: a model of impulse control disorders in Parkinson's disease.

Jiménez-Urbieta H, Gago B, Quiroga-Varela A, Rodríguez-Chinchilla T, Merino-Galán L, Oregi A, Belloso-Iguerategui A, Delgado-Alvarado M, Navalpotro-Gómez I, Marin C, Fernagut PO, Rodríguez-Oroz MC.

Neurobiol Aging. 2019 Mar;75:126-135. doi: 10.1016/j.neurobiolaging.2018.11.021. Epub 2018 Nov 24.

PMID:
30572183
7.

Using Kinect to classify Parkinson's disease stages related to severity of gait impairment.

Dranca L, de Abetxuko Ruiz de Mendarozketa L, Goñi A, Illarramendi A, Navalpotro Gomez I, Delgado Alvarado M, Rodríguez-Oroz MC.

BMC Bioinformatics. 2018 Dec 10;19(1):471. doi: 10.1186/s12859-018-2488-4.

8.

[«Apuntes en Neurologia» (Notes in Neurology): a synthesis of the evidence on common paroxysmal neurological disorders and on neurodegenerative disorders].

Toledo M, Carnero-Pardo C, Carreno-Martinez M, Escudero-Torrella J, Gaig C, Garcia-Ribas G, Gil-Nagel A, Grandas FJ, Kulisevsky J, Lainez-Andres JM, Pareja JA, Porta-Etessam J, Poza-Aldea JJ, Rodriguez-Oroz MC, Serratosa JM, Villanueva V.

Rev Neurol. 2018 Nov 26;67(s01):S1-S21. Review. Spanish.

PMID:
30484273
9.

Ratios of proteins in cerebrospinal fluid in Parkinson's disease cognitive decline: prospective study.

Delgado-Alvarado M, Dacosta-Aguayo R, Navalpotro-Gómez I, Gago B, Gorostidi A, Jiménez-Urbieta H, Quiroga-Varela A, Ruiz-Martínez J, Bergareche A, Rodríguez-Oroz MC.

Mov Disord. 2018 Nov;33(11):1809-1813. doi: 10.1002/mds.27518. Epub 2018 Nov 13.

PMID:
30423201
10.

Detecting Mild Cognitive Deficits in Parkinson's Disease: Comparison of Neuropsychological Tests.

Hoogland J, van Wanrooij LL, Boel JA, Goldman JG, Stebbins GT, Dalrymple-Alford JC, Marras C, Adler CH, Junque C, Pedersen KF, Mollenhauer B, Zabetian CP, Eslinger PJ, Lewis SJG, Wu RM, Klein M, Rodriguez-Oroz MC, Cammisuli DM, Barone P, Biundo R, de Bie RMA, Schmand BA, Tröster AI, Burn DJ, Litvan I, Filoteo JV, Geurtsen GJ, Weintraub D; IPMDS Study Group “Validation of Mild Cognitive Impairment in Parkinson Disease”.

Mov Disord. 2018 Nov;33(11):1750-1759. doi: 10.1002/mds.110. Epub 2018 Sep 14. Review.

11.

Pooled-DNA target sequencing of Parkinson genes reveals novel phenotypic associations in Spanish population.

Diez-Fairen M, Benitez BA, Ortega-Cubero S, Lorenzo-Betancor O, Cruchaga C, Lorenzo E, Samaranch L, Carcel M, Obeso JA, Rodriguez-Oroz MC, Aguilar M, Coria F, Pastor MA, Pastor P.

Neurobiol Aging. 2018 Oct;70:325.e1-325.e5. doi: 10.1016/j.neurobiolaging.2018.05.008. Epub 2018 May 14.

PMID:
29887346
12.

Transcriptomic integration of D4R and MOR signaling in the rat caudate putamen.

Valderrama-Carvajal A, Irizar H, Gago B, Jiménez-Urbieta H, Fuxe K, Rodríguez-Oroz MC, Otaegui D, Rivera A.

Sci Rep. 2018 May 9;8(1):7337. doi: 10.1038/s41598-018-25604-4.

13.

Subthalamotomy for Parkinson's disease: clinical outcome and topography of lesions.

Rodriguez-Rojas R, Carballo-Barreda M, Alvarez L, Guridi J, Pavon N, Garcia-Maeso I, Mací As R, Rodriguez-Oroz MC, Obeso JA.

J Neurol Neurosurg Psychiatry. 2018 Jun;89(6):572-578. doi: 10.1136/jnnp-2017-316241. Epub 2017 Dec 8.

PMID:
29222224
14.

Treatable inherited rare movement disorders.

Jinnah HA, Albanese A, Bhatia KP, Cardoso F, Da Prat G, de Koning TJ, Espay AJ, Fung V, Garcia-Ruiz PJ, Gershanik O, Jankovic J, Kaji R, Kotschet K, Marras C, Miyasaki JM, Morgante F, Munchau A, Pal PK, Rodriguez Oroz MC, Rodríguez-Violante M, Schöls L, Stamelou M, Tijssen M, Uribe Roca C, de la Cerda A, Gatto EM; International Parkinson's Disease Movement Disorders Society Task Force on Rare Movement Disorders.

Mov Disord. 2018 Jan;33(1):21-35. doi: 10.1002/mds.27140. Epub 2017 Sep 1. Review.

15.

Parkinson's disease with mild cognitive impairment: severe cortical thinning antedates dementia.

Gasca-Salas C, García-Lorenzo D, Garcia-Garcia D, Clavero P, Obeso JA, Lehericy S, Rodríguez-Oroz MC.

Brain Imaging Behav. 2019 Feb;13(1):180-188. doi: 10.1007/s11682-017-9751-6.

PMID:
28710667
16.

Tau/α-synuclein ratio and inflammatory proteins in Parkinson's disease: An exploratory study.

Delgado-Alvarado M, Gago B, Gorostidi A, Jiménez-Urbieta H, Dacosta-Aguayo R, Navalpotro-Gómez I, Ruiz-Martínez J, Bergareche A, Martí-Massó JF, Martínez-Lage P, Izagirre A, Rodríguez-Oroz MC.

Mov Disord. 2017 Jul;32(7):1066-1073. doi: 10.1002/mds.27001. Epub 2017 May 26.

PMID:
28548309
17.

Impulse control disorders and levodopa-induced dyskinesias in Parkinson's disease: an update.

Voon V, Napier TC, Frank MJ, Sgambato-Faure V, Grace AA, Rodriguez-Oroz M, Obeso J, Bezard E, Fernagut PO.

Lancet Neurol. 2017 Mar;16(3):238-250. doi: 10.1016/S1474-4422(17)30004-2. Epub 2017 Feb 15. Review.

PMID:
28229895
18.

Mitochondrial activity in the frontal cortex area 8 and angular gyrus in Parkinson's disease and Parkinson's disease with dementia.

Garcia-Esparcia P, Koneti A, Rodríguez-Oroz MC, Gago B, Del Rio JA, Ferrer I.

Brain Pathol. 2018 Jan;28(1):43-57. doi: 10.1111/bpa.12474. Epub 2017 Mar 16.

19.

Targeting of the Subthalamic Nucleus for Deep Brain Stimulation: A Survey Among Parkinson Disease Specialists.

Hamel W, Köppen JA, Alesch F, Antonini A, Barcia JA, Bergman H, Chabardes S, Contarino MF, Cornu P, Demmel W, Deuschl G, Fasano A, Kühn AA, Limousin P, McIntyre CC, Mehdorn HM, Pilleri M, Pollak P, Rodríguez-Oroz MC, Rumià J, Samuel M, Timmermann L, Valldeoriola F, Vesper J, Visser-Vandewalle V, Volkmann J, Lozano AM.

World Neurosurg. 2017 Mar;99:41-46. doi: 10.1016/j.wneu.2016.11.012. Epub 2016 Nov 9.

PMID:
27838430
20.

Stimulation sites in the subthalamic nucleus and clinical improvement in Parkinson's disease: a new approach for active contact localization.

Garcia-Garcia D, Guridi J, Toledo JB, Alegre M, Obeso JA, Rodríguez-Oroz MC.

J Neurosurg. 2016 Nov;125(5):1068-1079. Epub 2016 Feb 5.

PMID:
26848922
21.

Genetic Mutation Analysis of Parkinson's Disease Patients Using Multigene Next-Generation Sequencing Panels.

Gorostidi A, Martí-Massó JF, Bergareche A, Rodríguez-Oroz MC, López de Munain A, Ruiz-Martínez J.

Mol Diagn Ther. 2016 Oct;20(5):481-91. doi: 10.1007/s40291-016-0216-1.

PMID:
27294386
22.

Biomarkers for dementia and mild cognitive impairment in Parkinson's disease.

Delgado-Alvarado M, Gago B, Navalpotro-Gomez I, Jiménez-Urbieta H, Rodriguez-Oroz MC.

Mov Disord. 2016 Jun;31(6):861-81. doi: 10.1002/mds.26662. Epub 2016 May 19. Review.

PMID:
27193487
23.

Erratum to: COPPADIS-2015 (COhort of Patients with PArkinson's DIsease in Spain, 2015), a global--clinical evaluations, serum biomarkers, genetic studies and neuroimaging--prospective, multicenter, non-interventional, long-term study on Parkinson's disease progression.

Santos-García D, Mir P, Cubo E, Vela L, Rodríguez-Oroz MC, Martí MJ, Arbelo JM, Infante J, Kulisevsky J, Martínez-Martín P; COPPADIS Study Group.

BMC Neurol. 2016 Apr 6;16:44. doi: 10.1186/s12883-016-0567-6. No abstract available.

24.

COPPADIS-2015 (COhort of Patients with PArkinson's DIsease in Spain, 2015), a global--clinical evaluations, serum biomarkers, genetic studies and neuroimaging--prospective, multicenter, non-interventional, long-term study on Parkinson's disease progression.

Santos-García D, Mir P, Cubo E, Vela L, Rodríguez-Oroz MC, Martí MJ, Arbelo JM, Infante J, Kulisevsky J, Martínez-Martín P; COPPADIS Study Group.

BMC Neurol. 2016 Feb 25;16:26. doi: 10.1186/s12883-016-0548-9. Erratum in: BMC Neurol. 2016;16:44.

25.

DAT imaging and clinical biomarkers in relatives at genetic risk for LRRK2 R1441G Parkinson's disease.

Bergareche A, Rodríguez-Oroz MC, Estanga A, Gorostidi A, López de Munain A, Castillo-Triviño T, Ruiz-Martínez J, Mondragón E, Gaig C, Lomeña F, Sarasqueta C, Tolosa E, Martí-Massó JF.

Mov Disord. 2016 Mar;31(3):335-43. doi: 10.1002/mds.26478. Epub 2015 Dec 21.

PMID:
26686514
26.

Significance of visual hallucinations and cerebral hypometabolism in the risk of dementia in Parkinson's disease patients with mild cognitive impairment.

Gasca-Salas C, Clavero P, García-García D, Obeso JA, Rodríguez-Oroz MC.

Hum Brain Mapp. 2016 Mar;37(3):968-77. doi: 10.1002/hbm.23080. Epub 2015 Dec 14.

PMID:
26663702
27.

Dyskinesias and impulse control disorders in Parkinson's disease: From pathogenesis to potential therapeutic approaches.

Jiménez-Urbieta H, Gago B, de la Riva P, Delgado-Alvarado M, Marin C, Rodriguez-Oroz MC.

Neurosci Biobehav Rev. 2015 Sep;56:294-314. doi: 10.1016/j.neubiorev.2015.07.010. Epub 2015 Jul 26. Review.

PMID:
26216865
28.

From unilateral to bilateral parkinsonism: Effects of lateralization on dyskinesias and associated molecular mechanisms.

Marin C, Bonastre M, Mengod G, Cortés R, Rodríguez-Oroz MC.

Neuropharmacology. 2015 Oct;97:365-75. doi: 10.1016/j.neuropharm.2015.06.004. Epub 2015 Jun 22.

PMID:
26113400
29.

The relationship between atrophy and hypometabolism: is it regionally dependent in dementias?

Rodriguez-Oroz MC, Gago B, Clavero P, Delgado-Alvarado M, Garcia-Garcia D, Jimenez-Urbieta H.

Curr Neurol Neurosci Rep. 2015 Jul;15(7):44. doi: 10.1007/s11910-015-0562-0. Review.

PMID:
26008810
30.

Parkinsonism, cognitive deficit and behavioural disturbance caused by a novel mutation in the polymerase gamma gene.

Delgado-Alvarado M, de la Riva P, Jiménez-Urbieta H, Gago B, Gabilondo A, Bornstein B, Rodríguez-Oroz MC.

J Neurol Sci. 2015 Mar 15;350(1-2):93-7. doi: 10.1016/j.jns.2015.02.011. Epub 2015 Feb 11. Review.

PMID:
25724872
31.

Management of impulse control disorders in Parkinson's disease: Controversies and future approaches.

Samuel M, Rodriguez-Oroz M, Antonini A, Brotchie JM, Ray Chaudhuri K, Brown RG, Galpern WR, Nirenberg MJ, Okun MS, Lang AE.

Mov Disord. 2015 Feb;30(2):150-9. doi: 10.1002/mds.26099. Epub 2015 Jan 21. Review.

32.

Longitudinal assessment of the pattern of cognitive decline in non-demented patients with advanced Parkinson's disease.

Gasca-Salas C, Estanga A, Clavero P, Aguilar-Palacio I, González-Redondo R, Obeso JA, Rodríguez-Oroz MC.

J Parkinsons Dis. 2014;4(4):677-86. doi: 10.3233/JPD-140398.

PMID:
25208730
33.

Cognitive dysfunction in Parkinson's disease related to the R1441G mutation in LRRK2.

Estanga A, Rodriguez-Oroz MC, Ruiz-Martinez J, Barandiaran M, Gorostidi A, Bergareche A, Mondragon E, Lopez de Munain A, Marti-Masso JF.

Parkinsonism Relat Disord. 2014 Oct;20(10):1097-100. doi: 10.1016/j.parkreldis.2014.07.005. Epub 2014 Jul 30.

PMID:
25127457
34.

The expanding universe of disorders of the basal ganglia.

Obeso JA, Rodriguez-Oroz MC, Stamelou M, Bhatia KP, Burn DJ.

Lancet. 2014 Aug 9;384(9942):523-31. doi: 10.1016/S0140-6736(13)62418-6. Epub 2014 Jun 18. Review.

PMID:
24954674
35.

Grey matter hypometabolism and atrophy in Parkinson's disease with cognitive impairment: a two-step process.

González-Redondo R, García-García D, Clavero P, Gasca-Salas C, García-Eulate R, Zubieta JL, Arbizu J, Obeso JA, Rodríguez-Oroz MC.

Brain. 2014 Aug;137(Pt 8):2356-67. doi: 10.1093/brain/awu159. Epub 2014 Jun 20.

36.

The subthalamic nucleus and inhibitory control: impact of subthalamotomy in Parkinson's disease.

Obeso I, Wilkinson L, Casabona E, Speekenbrink M, Luisa Bringas M, Álvarez M, Álvarez L, Pavón N, Rodríguez-Oroz MC, Macías R, Obeso JA, Jahanshahi M.

Brain. 2014 May;137(Pt 5):1470-80. doi: 10.1093/brain/awu058. Epub 2014 Mar 22.

PMID:
24657985
37.

High beta activity in the subthalamic nucleus and freezing of gait in Parkinson's disease.

Toledo JB, López-Azcárate J, Garcia-Garcia D, Guridi J, Valencia M, Artieda J, Obeso J, Alegre M, Rodriguez-Oroz M.

Neurobiol Dis. 2014 Apr;64:60-5. doi: 10.1016/j.nbd.2013.12.005. Epub 2013 Dec 17.

PMID:
24361601
38.

Prevalence of cancer in Parkinson's disease related to R1441G and G2019S mutations in LRRK2.

Ruiz-Martínez J, de la Riva P, Rodríguez-Oroz MC, Mondragón Rezola E, Bergareche A, Gorostidi A, Gago B, Estanga A, Larrañaga N, Sarasqueta C, López de Munain A, Martí Massó JF.

Mov Disord. 2014 May;29(6):750-5. doi: 10.1002/mds.25778. Epub 2013 Dec 19.

PMID:
24357540
39.

Short and long term outcome of bilateral pallidal stimulation in chorea-acanthocytosis.

Miquel M, Spampinato U, Latxague C, Aviles-Olmos I, Bader B, Bertram K, Bhatia K, Burbaud P, Burghaus L, Cho JW, Cuny E, Danek A, Foltynie T, Garcia Ruiz PJ, Giménez-Roldán S, Guehl D, Guridi J, Hariz M, Jarman P, Kefalopoulou ZM, Limousin P, Lipsman N, Lozano AM, Moro E, Ngy D, Rodriguez-Oroz MC, Shang H, Shin H, Walker RH, Yokochi F, Zrinzo L, Tison F.

PLoS One. 2013 Nov 5;8(11):e79241. doi: 10.1371/journal.pone.0079241. eCollection 2013.

40.

Subthalamic 6-OHDA-induced lesion attenuates levodopa-induced dyskinesias in the rat model of Parkinson's disease.

Marin C, Bonastre M, Mengod G, Cortés R, Rodríguez-Oroz MC, Obeso JA.

Exp Neurol. 2013 Dec;250:304-12. doi: 10.1016/j.expneurol.2013.10.006. Epub 2013 Oct 18.

PMID:
24140562
41.

Commentary.

Rodriguez-Oroz MC, Obeso JA.

Mov Disord. 2013 Sep;28(10):1349-50. doi: 10.1002/mds.25681. No abstract available.

PMID:
24078331
42.

Bilateral stimulation of the subthalamic nucleus has differential effects on reactive and proactive inhibition and conflict-induced slowing in Parkinson's disease.

Obeso I, Wilkinson L, Rodríguez-Oroz MC, Obeso JA, Jahanshahi M.

Exp Brain Res. 2013 May;226(3):451-62. doi: 10.1007/s00221-013-3457-9. Epub 2013 Mar 23.

PMID:
23525560
43.

Influence of microRNA deregulation on chaperone-mediated autophagy and α-synuclein pathology in Parkinson's disease.

Alvarez-Erviti L, Seow Y, Schapira AH, Rodriguez-Oroz MC, Obeso JA, Cooper JM.

Cell Death Dis. 2013 Mar 14;4:e545. doi: 10.1038/cddis.2013.73.

44.

Effect of deep brain stimulation of the subthalamic nucleus on non-motor fluctuations in Parkinson's disease: two-years' follow-up.

Ortega-Cubero S, Clavero P, Irurzun C, Gonzalez-Redondo R, Guridi J, Obeso JA, Rodriguez-Oroz MC.

Parkinsonism Relat Disord. 2013 May;19(5):543-7. doi: 10.1016/j.parkreldis.2013.02.001. Epub 2013 Feb 27.

PMID:
23453890
45.

l-dopa-induced dyskinesias in unilateral 6-hydroxydopamine-lesioned rats are not modified by excitotoxic lesion of the entopeduncular nucleus and substantia nigra pars reticulata.

Gago B, Marin C, Rodríguez-Oroz MC, Obeso JA.

Synapse. 2013 Jul;67(7):407-14. doi: 10.1002/syn.21652. Epub 2013 Apr 2.

PMID:
23404474
46.
47.

Long-term outcomes of surgical therapies for Parkinson's disease.

Rodriguez-Oroz MC, Moro E, Krack P.

Mov Disord. 2012 Dec;27(14):1718-28. doi: 10.1002/mds.25214. Epub 2012 Dec 3. Review.

PMID:
23208668
48.

The subthalamic nucleus is involved in successful inhibition in the stop-signal task: a local field potential study in Parkinson's disease.

Alegre M, Lopez-Azcarate J, Obeso I, Wilkinson L, Rodriguez-Oroz MC, Valencia M, Garcia-Garcia D, Guridi J, Artieda J, Jahanshahi M, Obeso JA.

Exp Neurol. 2013 Jan;239:1-12. doi: 10.1016/j.expneurol.2012.08.027. Epub 2012 Sep 4.

PMID:
22975442
49.

Posterior parietooccipital hypometabolism may differentiate mild cognitive impairment from dementia in Parkinson's disease.

Garcia-Garcia D, Clavero P, Gasca Salas C, Lamet I, Arbizu J, Gonzalez-Redondo R, Obeso JA, Rodriguez-Oroz MC.

Eur J Nucl Med Mol Imaging. 2012 Nov;39(11):1767-77. doi: 10.1007/s00259-012-2198-5. Epub 2012 Aug 8.

PMID:
22872307
50.

Subthalamic activity during diphasic dyskinesias in Parkinson's disease.

Alegre M, López-Azcárate J, Alonso-Frech F, Rodríguez-Oroz MC, Valencia M, Guridi J, Artieda J, Obeso JA.

Mov Disord. 2012 Aug;27(9):1178-81. doi: 10.1002/mds.25090. Epub 2012 Jun 28.

PMID:
22744752

Supplemental Content

Loading ...
Support Center